Many of the bispecific antibodies (BsAbs) approved by global regulators have yet to demonstrate robust clinical benefit ...

Government plans to bar cough syrups for children under two and discourage use below five under draft NFI 2026 amid safety ...

Health Ministry is reportedly considering banning prescriptions of paediatric cough syrups for children under two years and ...

Global pharmaceutical leader Lupin Limited (Lupin) BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced the launch of Dapagliflozin Tablets, 5 mg and 10 mg, in the United ...

This regulatory tightening follows alarm over discovery of toxic industrial solvents, including diethylene glycol (DEG) and ...

I initiate coverage on Forte Biosciences stock at a 'Hold' rating due to both pipeline risk and upcoming clinical catalysts.

India may ban cough syrups for children under 2 and restrict use for those under 5 under draft NFI 2026 after ...

Trump subsequently retreated from his threats of military annexation, telling world leaders gathered at Davos that he "won't ...

The company has increased its payouts over the past five years despite significant challenges.

Medicus Pharma (NASDAQ:MDCX) earlier this week outlined progress in the development of its investigational therapy Teverelix, ...

Jaguar Health Inc (JAGX) reports a 5% revenue increase and a transformative partnership, despite facing operational losses and regulatory hurdles.

Sparian Biosciences begins phase 1 clinical trial of SBS-147; a next generation arylepoxamide receptor agonist to treat pain: New York Saturday, April 11, 2026, 15:00 Hrs [IST] Sp ...